APGE

Apogee Therapeutics Inc

Oct 20 • 04:00PM ET

56.94

+1.79 3.25 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BMRN SRPT IONS ALNY QURE CRSP NTLA SGMO

| Held by: XBI VTI IWM VXF IWO IBB SCHA VTWO LABU ITOT

Index	RUT	P/E	-	EPS (ttm)	-4.08	Insider Own	33.60%	Shs Outstand	46.10M	Perf Week	5.50%
Market Cap	3.79B	Forward P/E	-	EPS next Y	-5.21	Insider Trans	-0.12%	Shs Float	39.57M	Perf Month	55.87%
Enterprise Value	3.29B	PEG	-	EPS next Q	-1.20	Inst Own	83.20%	Short Float	23.88%	Perf Quarter	43.79%
Income	-237.67M	P/S	-	EPS this Y	-36.44%	Inst Trans	-1.34%	Short Ratio	14.39	Perf Half Y	73.33%
Sales	0.00M	P/B	5.48	EPS next Y	-15.68%	ROA	-32.59%	Short Interest	9.45M	Perf YTD	25.70%
Book/sh	10.39	P/C	7.50	EPS next 5Y	-23.43%	ROE	-34.12%	52W High	63.50 -10.33%	Perf Year	0.25%
Cash/sh	7.59	P/FCF	-	EPS past 3/5Y	-105.02% -	ROIC	-37.95%	52W Low	26.20 117.33%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.02% 5.83%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-79.09%	Oper. Margin	-	ATR (14)	2.59	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	16.36	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	75.97	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	16.36	EPS Q/Q	-89.04%	SMA20	25.02%	Beta	1.24	Target Price	92.75
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	40.36%	Rel Volume	1.26	Prev Close	55.15
Employees	196	LT Debt/Eq	0.01	Earnings	Aug 11 BMO	SMA200	45.98%	Avg Volume	656.64K	Price	56.94
IPO	Jul 14, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3.29% -	Trades		Volume	830,411	Change	3.25%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-25-25	Initiated	RBC Capital Mkts	Outperform	$60
Jul-07-25	Reiterated	BTIG Research	Buy	$100 → $115
Mar-13-25	Initiated	Citigroup	Buy	$95
Nov-25-24	Initiated	Canaccord Genuity	Buy	$89
May-10-24	Initiated	BofA Securities	Buy	$80
Dec-20-23	Initiated	BTIG Research	Buy	$43
Aug-08-23	Initiated	Wedbush	Outperform	$40
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Stifel	Buy	$34
Aug-08-23	Initiated	Jefferies	Buy	$29
Aug-08-23	Initiated	Guggenheim	Buy	$29

Show Previous Ratings

Oct-17-25 09:55PM	BTIG Maintains a Buy on Apogee Therapeutics (APGE) (Insider Monkey)
Oct-14-25 09:55AM	Does Apogee Therapeutics Inc. (APGE) Have the Potential to Rally 72.52% as Wall Street Analysts Expect? (Zacks)
Oct-10-25 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million (GlobeNewswire)
Oct-09-25 05:26PM	Why Apogee Therapeutics Stock Triumphed on Thursday (Motley Fool) +12.64%
01:08PM	Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out (Investor's Business Daily)
09:52PM	Loading…
Oct-08-25 09:52PM	Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering (GlobeNewswire) +18.90%
04:01PM	Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering (GlobeNewswire)
Sep-30-25 04:00AM	RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) With an Outperform Rating (Insider Monkey)
Sep-15-25 09:09AM	BofA Raises Apogee Therapeutics (APGE) PT to $87 Following Positive Phase 2 APEX Trial Results for Atopic Dermatitis (Insider Monkey)
Sep-11-25 07:30AM	Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress (GlobeNewswire)
Sep-03-25 07:30AM	Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum (GlobeNewswire)
Aug-11-25 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-06-25 09:55AM	Wall Street Analysts See a 152.41% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? (Zacks) -5.24%
Jul-31-25 11:38AM	Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug (Insider Monkey)
Jul-16-25 09:38AM	BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating (Insider Monkey)
07:52AM	Loading…
Jul-14-25 07:52AM	Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE) (Insider Monkey)
Jul-08-25 03:31PM	Regeneron's Blockbuster Dupixent Faces a New Rival (Barrons.com) -7.21%
02:26PM	Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors (Insider Monkey)
Jul-07-25 04:27PM	Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker. (Investor's Business Daily) -17.32%
10:09AM	Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot (Investor's Business Daily)
06:00AM	Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Jul-06-25 06:00PM	Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025 (GlobeNewswire)
04:01AM	Apogee Therapeutics Shares Positive Interim Phase 1b Results for APG808 in Asthma (Insider Monkey)
Jun-09-25 09:55AM	Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? (Zacks)
May-29-25 07:30AM	Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-25 09:55AM	Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet (Zacks)
May-12-25 02:21PM	Why Is Apogee Therapeutics Stock Trading Higher On Monday? (Benzinga) +6.14%
06:05AM	Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody, in Patients with Mild-to-Moderate Asthma (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4R Antibody, in Patients with Mild-to-Moderate Asthma (GlobeNewswire)
09:55AM	Loading…
May-05-25 09:55AM	Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's is How to Trade (Zacks)
May-01-25 08:00AM	Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference (GlobeNewswire)
Apr-14-25 08:04AM	Apogee Therapeutics: Engineering Biologic Dominance (Seeking Alpha)
Mar-26-25 05:50PM	Is Apogee Therapeutics (APGE) Among the Best IPO Stocks to Buy in 2025? (InsiderMonkey)
Mar-03-25 12:16PM	Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial (Benzinga)
06:05AM	Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990) (GlobeNewswire)
Mar-01-25 09:22AM	Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now? (Insider Monkey)
Feb-28-25 04:00PM	Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025 (GlobeNewswire)
Feb-25-25 07:30AM	Apogee Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-03-25 07:00AM	Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Jan-30-25 03:44PM	Heres Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025 (Insider Monkey) +5.41%
Jan-29-25 07:30AM	Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-10-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions (GlobeNewswire)
Dec-03-24 06:52AM	Apogee Therapeutics Advances in I&I Disease Treatments (TipRanks)
Dec-02-24 06:00AM	Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day (GlobeNewswire)
Nov-29-24 01:00PM	Apogee Therapeutics Announces Agenda for Virtual R&D Day (GlobeNewswire)
Nov-18-24 07:30AM	Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 (GlobeNewswire)
Nov-13-24 07:21AM	Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028 (TipRanks) -7.95%
Nov-12-24 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results (GlobeNewswire) -5.14%
Nov-04-24 07:30AM	Apogee Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-24-24 08:00AM	Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
Oct-16-24 07:00AM	Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting (GlobeNewswire)
Oct-07-24 04:50PM	Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now (Insider Monkey)
Oct-04-24 01:03PM	Wellington Management Group LLP Increases Stake in Apogee Therapeutics Inc (GuruFocus.com)
Sep-12-24 07:00AM	Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit (GlobeNewswire)
Sep-09-24 07:00AM	Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer (GlobeNewswire)
Sep-07-24 01:45AM	Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Aug-24-24 01:30AM	Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Aug-19-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire) +10.59%
Aug-12-24 06:30AM	Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results (GlobeNewswire) +9.78%
Aug-10-24 01:00AM	Apogee Therapeutics Inc (APGE) CEO Michael Henderson Sells 40,000 Shares (GuruFocus.com)
01:00AM	Insider Sale: Carl Dambkowski Sells 7,335 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire)
Jul-06-24 01:00AM	Insider Sale: CEO Michael Henderson Sells 15,000 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
01:00AM	Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
May-28-24 07:30AM	Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD (GlobeNewswire)
May-23-24 07:30AM	Apogee Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-15-24 04:01PM	Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
May-13-24 01:53PM	APGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:42AM	Apogee Therapeutics' Q1 Net Loss Widens (MT Newswires)
07:00AM	Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-10-24 10:13AM	BofA Securities Starts Coverage on Apogee Therapeutics With Buy Rating, $80 Price Target (MT Newswires)
May-08-24 01:28PM	Earnings Superstars: 3 Stocks Primed to Outperform This Quarter (InvestorPlace)
May-06-24 08:00AM	Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference (GlobeNewswire)
Apr-03-24 07:49AM	Paragons hub-and-spoke biotech model yields another reverse merger (BioPharma Dive)
Mar-28-24 11:01AM	Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why (Zacks)
Mar-25-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases (GlobeNewswire) -5.01%
07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4R Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases (GlobeNewswire)
Mar-12-24 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million (GlobeNewswire)
Mar-07-24 06:49PM	Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering (GlobeNewswire)
Mar-05-24 10:53PM	APGE Stock Earnings: Apogee Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +42.07% +12.46%
04:23PM	Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering (GlobeNewswire)
04:16PM	Apogee Catapults 42% After Eczema Drug Blows Expectations Out Of The Water (Investor's Business Daily)
07:35AM	IPO Stock Apogee Shifts Higher On Solid Phase 1 Outcome (Investor's Business Daily)
07:35AM	IPO Stock Apogee Rockets On Solid Phase 1 Outcome (Investor's Business Daily)
06:10AM	Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
06:00AM	Apogee data hint at potential for long-lasting eczema drug (BioPharma Dive)
06:00AM	Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days (GlobeNewswire)
Mar-04-24 04:01PM	Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024 (GlobeNewswire) +12.08%
Jan-02-24 07:30AM	Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-15-23 04:44AM	Apogee Therapeutics Inc Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com)
Nov-13-23 07:30AM	Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results (GlobeNewswire) +7.32%
Oct-30-23 08:00AM	Apogee Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire) +5.77%
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace) -8.07%
Sep-27-23 08:42AM	Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress (GlobeNewswire)
Sep-14-23 07:30AM	Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day (GlobeNewswire)
Aug-29-23 08:00AM	Paragon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee Therapeutics (PR Newswire)
Aug-28-23 07:30AM	Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-21-23 07:30AM	Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board (GlobeNewswire)

Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dambkowski Carl	Chief Medical Officer	Oct 01 '25	Option Exercise	22.86	2,385	54,521	289,843	Oct 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Oct 01 '25	Sale	39.80	5,110	203,378	284,733	Oct 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Sep 03 '25	Sale	37.87	2,725	103,198	233,548	Sep 05 08:00 PM
Dambkowski Carl	Chief Medical Officer	Aug 06 '25	Sale	37.78	2,725	102,950	236,273	Aug 08 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jul 02 '25	Option Exercise	22.86	7,365	168,364	249,088	Jul 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jul 02 '25	Sale	45.09	10,090	454,954	238,998	Jul 03 08:00 PM
CARL DAMBKOWSKI	Officer	Jul 02 '25	Proposed Sale	44.26	22,345	988,990		Jul 02 04:22 PM
Dambkowski Carl	Chief Medical Officer	Jun 04 '25	Sale	36.96	2,725	100,716	241,723	Jun 06 08:01 PM
Dambkowski Carl	Chief Medical Officer	May 07 '25	Sale	35.75	2,725	97,419	244,448	May 09 08:01 PM
Dambkowski Carl	Chief Medical Officer	Apr 02 '25	Sale	36.22	3,860	139,801	247,173	Apr 04 08:01 PM
CARL DAMBKOWSKI	Officer	Apr 02 '25	Proposed Sale	35.61	9,310	331,529		Apr 02 04:23 PM
Dambkowski Carl	Chief Medical Officer	Mar 05 '25	Sale	30.48	1,590	48,463	251,033	Mar 07 08:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Mar 05 '25	Sale	30.15	10,000	301,511	1,292,987	Mar 07 08:01 PM
HENDERSON MICHAEL THOMAS	Officer	Mar 05 '25	Proposed Sale	30.15	10,000	301,501		Mar 05 01:46 PM
Dambkowski Carl	Chief Medical Officer	Feb 05 '25	Option Exercise	22.86	795	18,174	256,143	Feb 07 08:02 PM
Dambkowski Carl	Chief Medical Officer	Feb 05 '25	Sale	40.69	3,520	143,229	252,623	Feb 07 08:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Feb 05 '25	Sale	40.58	15,000	608,700	1,302,987	Feb 07 08:01 PM
HENDERSON MICHAEL THOMAS	Director	Feb 05 '25	Proposed Sale	40.58	15,000	608,728		Feb 05 02:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jan 31 '25	Option Exercise	22.86	8,500	194,310	1,317,987	Jan 31 08:00 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jan 08 '25	Sale	48.85	15,000	732,693	1,309,487	Jan 10 08:00 PM
HENDERSON MICHAEL THOMAS	Officer	Jan 08 '25	Proposed Sale	48.84	15,000	732,675		Jan 08 12:23 PM
Dambkowski Carl	Chief Medical Officer	Jan 02 '25	Option Exercise	22.86	1,360	31,090	259,433	Jan 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jan 02 '25	Sale	46.94	4,085	191,740	255,348	Jan 03 08:00 PM
McKenna Mark C.	Director	Dec 12 '24	Buy	49.54	20,000	990,775	20,000	Dec 16 06:00 AM
Dambkowski Carl	Chief Medical Officer	Dec 11 '24	Option Exercise	22.86	1,815	41,491	262,613	Dec 13 08:01 PM
Dambkowski Carl	Chief Medical Officer	Dec 11 '24	Sale	48.76	4,540	221,363	258,073	Dec 13 08:01 PM
CARL DAMBKOWSKI	Officer	Dec 11 '24	Proposed Sale	48.38	18,160	878,581		Dec 11 04:59 PM
Dambkowski Carl	Chief Medical Officer	Dec 04 '24	Sale	46.07	6,665	307,057	260,798	Dec 06 08:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Dec 04 '24	Sale	46.58	15,000	698,654	1,324,487	Dec 06 08:01 PM
HENDERSON MICHAEL THOMAS	Officer	Dec 04 '24	Proposed Sale	46.58	15,000	698,709		Dec 04 11:12 AM
Dambkowski Carl	Chief Medical Officer	Nov 06 '24	Sale	59.12	6,665	394,041	267,463	Nov 08 08:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Nov 06 '24	Sale	59.22	15,000	888,320	1,339,487	Nov 08 08:01 PM
HENDERSON MICHAEL THOMAS	Officer	Nov 06 '24	Proposed Sale	59.23	15,000	888,388		Nov 06 11:39 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

APGE

Apogee Therapeutics Inc

Upgrade your FINVIZ experience